Targeted radiation therapy for recurrent high-grade glioma
Part of Cancer clinical trials.
This trial tests a new radiation treatment that targets tumor cells directly. It may help people with a specific type of aggressive brain tumor that has grown after standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old.
- You have a high-grade glioma (grade 3 or 4) that has grown after standard treatment like surgery, radiation, or chemotherapy.
- Your tumor is in one area and meets specific size limits after biopsy or surgery.
- You are able to care for yourself (Karnofsky score above 70).
- You do not need urgent surgery or have serious complications from previous treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of targeted radiation therapy for people with high-grade glioma (grade 3 or 4) that has not progressed after standard treatment. The therapy uses a radioactive substance attached to a protein that targets tumor cells, aiming to deliver radiation directly to the cancer.
This trial tests whether adding a precise, MRI-guided radiation treatment to tumor-treating electric fields (TTFields) can help people with recurrent glioblastoma. You may qualify if your tumor has come back 1 to 3 times after standard therapy and you haven't had certain prior treatments.
This trial studies a targeted medicine approach for high-grade glioma (a fast-growing brain tumor) and some diffuse midline tumors, including DIPG. It may help by matching treatment to tumor biology using tumor testing done before or around starting standard therapy.
This trial studies giving cetuximab (a targeted antibody) directly into an artery along with repeat radiation to treat certain recurring or treatment-resistant brain tumors. It may help by delivering the drug more directly to tumor areas and testing whether this approach can control the disease after it comes back.
This Phase 1 trial tests a new cancer drug (WSD0628) given with radiation for people whose high-grade glioma has returned after prior treatment. The goal is to find a safe dose and see how well the treatment works in this situation.
This study tests a light-activated therapy (radiodynamic therapy) using a special medicine to help treat a brain tumor that has come back after prior treatment. It may be offered after doctors decide you need further radiation for your recurrence.
Hear when a new Glioblastoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.